Literature DB >> 33413142

General practitioners' deprescribing decisions in older adults with polypharmacy: a case vignette study in 31 countries.

Katharina Tabea Jungo1, Sophie Mantelli1, Zsofia Rozsnyai1, Aristea Missiou2, Biljana Gerasimovska Kitanovska3, Birgitta Weltermann4,5, Christian Mallen6, Claire Collins7, Daiana Bonfim8, Donata Kurpas9, Ferdinando Petrazzuoli10, Gindrovel Dumitra11, Hans Thulesius10,12, Heidrun Lingner13, Kasper Lorenz Johansen14, Katharine Wallis15, Kathryn Hoffmann16, Lieve Peremans17,18, Liina Pilv19, Marija Petek Šter20, Markus Bleckwenn21, Martin Sattler22, Milly van der Ploeg23, Péter Torzsa24, Petra Bomberová Kánská25, Shlomo Vinker26, Radost Assenova27, Raquel Gomez Bravo28, Rita P A Viegas29, Rosy Tsopra30,31, Sanda Kreitmayer Pestic32, Sandra Gintere33, Tuomas H Koskela34, Vanja Lazic35, Victoria Tkachenko36, Emily Reeve37,38, Clare Luymes23,39, Rosalinde K E Poortvliet23, Nicolas Rodondi1,40, Jacobijn Gussekloo23,41, Sven Streit42.   

Abstract

BACKGROUND: General practitioners (GPs) should regularly review patients' medications and, if necessary, deprescribe, as inappropriate polypharmacy may harm patients' health. However, deprescribing can be challenging for physicians. This study investigates GPs' deprescribing decisions in 31 countries.
METHODS: In this case vignette study, GPs were invited to participate in an online survey containing three clinical cases of oldest-old multimorbid patients with potentially inappropriate polypharmacy. Patients differed in terms of dependency in activities of daily living (ADL) and were presented with and without history of cardiovascular disease (CVD). For each case, we asked GPs if they would deprescribe in their usual practice. We calculated proportions of GPs who reported they would deprescribe and performed a multilevel logistic regression to examine the association between history of CVD and level of dependency on GPs' deprescribing decisions.
RESULTS: Of 3,175 invited GPs, 54% responded (N = 1,706). The mean age was 50 years and 60% of respondents were female. Despite differences across GP characteristics, such as age (with older GPs being more likely to take deprescribing decisions), and across countries, overall more than 80% of GPs reported they would deprescribe the dosage of at least one medication in oldest-old patients (> 80 years) with polypharmacy irrespective of history of CVD. The odds of deprescribing was higher in patients with a higher level of dependency in ADL (OR =1.5, 95%CI 1.25 to 1.80) and absence of CVD (OR =3.04, 95%CI 2.58 to 3.57).
INTERPRETATION: The majority of GPs in this study were willing to deprescribe one or more medications in oldest-old multimorbid patients with polypharmacy. Willingness was higher in patients with increased dependency in ADL and lower in patients with CVD.

Entities:  

Keywords:  Deprescribing; Multimorbidity; Old age; Polypharmacy; Primary health care

Mesh:

Year:  2021        PMID: 33413142      PMCID: PMC7792080          DOI: 10.1186/s12877-020-01953-6

Source DB:  PubMed          Journal:  BMC Geriatr        ISSN: 1471-2318            Impact factor:   3.921


  53 in total

1.  Long-term cognitive and functional effects of potentially inappropriate medications in older women.

Authors:  Alain Koyama; Michael Steinman; Kristine Ensrud; Teresa A Hillier; Kristine Yaffe
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-11-29       Impact factor: 6.053

2.  Risk factors for falling among community-based seniors.

Authors:  Paula C Fletcher; Katherine Berg; Dawn M Dalby; John P Hirdes
Journal:  J Patient Saf       Date:  2009-06       Impact factor: 2.844

3.  General practice postal surveys: a questionnaire too far?

Authors:  B R McAvoy; E F Kaner
Journal:  BMJ       Date:  1996-09-21

Review 4.  Challenges of deprescribing in the multimorbid patient.

Authors:  Shane Cullinan; Christina Raae Hansen; Stephen Byrne; Denis O'Mahony; Patricia Kearney; Laura Sahm
Journal:  Eur J Hosp Pharm       Date:  2017-01

5.  Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients.

Authors:  Hilary Hamilton; Paul Gallagher; Cristin Ryan; Stephen Byrne; Denis O'Mahony
Journal:  Arch Intern Med       Date:  2011-06-13

Review 6.  A Systematic Review of the Impact of Potentially Inappropriate Medication on Health Care Utilization and Costs Among Older Adults.

Authors:  Virva Hyttinen; Johanna Jyrkkä; Hannu Valtonen
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

7.  Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France.

Authors:  Marie Herr; Helene Grondin; Stéphane Sanchez; Didier Armaingaud; Caroline Blochet; Antoine Vial; Philippe Denormandie; Joël Ankri
Journal:  Eur J Clin Pharmacol       Date:  2017-01-16       Impact factor: 2.953

Review 8.  Pharmacokinetic and pharmacodynamic alterations in older people with dementia.

Authors:  Emily Reeve; Shanna C Trenaman; Kenneth Rockwood; Sarah N Hilmer
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-05-10       Impact factor: 4.481

9.  Physician Perspectives on Deprescribing Cardiovascular Medications for Older Adults.

Authors:  Parag Goyal; Timothy S Anderson; Gwen M Bernacki; Zachary A Marcum; Ariela R Orkaby; Dae Kim; Andrew Zullo; Ashok Krishnaswami; Arlene Weissman; Michael A Steinman; Michael W Rich
Journal:  J Am Geriatr Soc       Date:  2019-09-11       Impact factor: 5.562

10.  How general practitioners would deprescribe in frail oldest-old with polypharmacy - the LESS study.

Authors:  Sophie Mantelli; Katharina Tabea Jungo; Zsofia Rozsnyai; Emily Reeve; Clare H Luymes; Rosalinde K E Poortvliet; Arnaud Chiolero; Nicolas Rodondi; Jacobijn Gussekloo; Sven Streit
Journal:  BMC Fam Pract       Date:  2018-10-12       Impact factor: 2.497

View more
  7 in total

1.  Prevalence of polypharmacy in community-dwelling older adults from seven centres in five European countries: a cross-sectional study of DO-HEALTH.

Authors:  Caroline de Godoi Rezende Costa Molino; Patricia O Chocano-Bedoya; Angélique Sadlon; Robert Theiler; John E Orav; Bruno Vellas; Rene Rizzoli; Reto W Kressig; John A Kanis; Sophie Guyonnet; Wei Lang; Andreas Egli; Heike A Bischoff-Ferrari
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

2.  Polypharmacy trajectories among older women with and without dementia: A longitudinal cohort study.

Authors:  Kailash Thapaliya; Melissa L Harris; Julie E Byles
Journal:  Explor Res Clin Soc Pharm       Date:  2021-08-05

3.  Primary care physicians' approaches to low-value prescribing in older adults: a qualitative study.

Authors:  Aimee N Pickering; Eric L Walter; Alicia Dawdani; Alison Decker; Megan E Hamm; Walid F Gellad; Thomas R Radomski
Journal:  BMC Geriatr       Date:  2022-02-24       Impact factor: 3.921

4.  Evaluation of changes in prescription among Japanese elderly patients before and after transition to home care.

Authors:  Shoichi Masumoto; Mikiya Sato; Tomotsugu Yamakawa; Shuhei Hamada; Takashi Inaba; Yoshihiro Kataoka; Sachiko Ozone; Shoji Yokoya; Jun Hamano
Journal:  J Gen Fam Med       Date:  2021-11-08

5.  Prescription Rates, Polypharmacy and Prescriber Variability in Swiss General Practice-A Cross-Sectional Database Study.

Authors:  Yael Rachamin; Levy Jäger; Rahel Meier; Thomas Grischott; Oliver Senn; Jakob M Burgstaller; Stefan Markun
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

6.  Development and Validation of Comprehensive Healthcare Providers' Opinions, Preferences, and Attitudes towards Deprescribing (CHOPPED Questionnaire).

Authors:  Iva Bužančić; Maja Ortner Hadžiabdić
Journal:  Pharmacy (Basel)       Date:  2022-07-01

7.  Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial.

Authors:  Katharina Tabea Jungo; Rahel Meier; Fabio Valeri; Nathalie Schwab; Claudio Schneider; Emily Reeve; Marco Spruit; Matthias Schwenkglenks; Nicolas Rodondi; Sven Streit
Journal:  BMC Fam Pract       Date:  2021-06-22       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.